Management of Graves Thyroidal and Extrathyroidal Disease: An Update

Лечение тиреальной и внесердечной болезни Грейвса: обновление
George Jean Kahaly
2020-09-14

Graves disease (GD)Graves orbitopathy (GO)radioactive iodine (RAI) and total thyroidectomy (TX)thionamides (methimazole, MMI)thyrotropin receptor antibodies (TSH-R-Abs)
CONTEXT: Invited update on the management of systemic autoimmune Graves disease (GD) and associated Graves orbitopathy (GO). EVIDENCE ACQUISITION: Guidelines, pertinent original articles, systemic reviews, and meta-analyses. EVIDENCE SYNTHESIS: Thyrotropin receptor antibodies (TSH-R-Abs), foremost the stimulatory TSH-R-Abs, are a specific biomarker for GD. Their measurement assists in the differential diagnosis of hyperthyroidism and offers accurate and rapid diagnosis of GD. Thyroid ultrasound is a sensitive imaging tool for GD. Worldwide, thionamides are the favored treatment (12-18 months) of newly diagnosed GD, with methimazole (MMI) as the preferred drug. Patients with persistently high TSH-R-Abs and/or persistent hyperthyroidism at 18 months, or with a relapse after completing a course of MMI, can opt for a definitive therapy with radioactive iodine (RAI) or total thyroidectomy (TX). Continued long-term, low-dose MMI administration is a valuable and safe alternative. Patient choice, both at initial presentation of GD and at recurrence, should be emphasized. Propylthiouracil is preferred to MMI during the first trimester of pregnancy. TX is best performed by a high-volume thyroid surgeon. RAI should be avoided in GD patients with active GO, especially in smokers. Recently, a promising therapy with an anti-insulin-like growth factor-1 monoclonal antibody for patients with active/severe GO was approved by the Food and Drug Administration. COVID-19 infection is a risk factor for poorly controlled hyperthyroidism, which contributes to the infection-related mortality risk. If GO is not severe, systemic steroid treatment should be postponed during COVID-19 while local treatment and preventive measures are offered. CONCLUSIONS: A clear trend towards serological diagnosis and medical treatment of GD has emerged.
1
COVID-19 infection worsens control of hyperthyroidism and increases infection-related mortality risk; systemic steroids for non-severe GO should be postponed during COVID-19, favoring local treatments and prevention.
2
Overall trend: movement toward serological diagnosis and medical (rather than immediate definitive) treatment of Graves disease.
3
Patients with persistent high TSH-R-Abs or hyperthyroidism at 18 months, or relapse after MMI, may choose definitive therapy with radioactive iodine (RAI) or total thyroidectomy (TX); long-term low-dose MMI is a safe alternative.
4
Propylthiouracil is preferred over MMI during the first trimester of pregnancy, and thyroidectomy is best performed by a high-volume thyroid surgeon.
5
RAI should be avoided in patients with active Graves orbitopathy (GO), especially smokers; an anti–insulin-like growth factor-1 monoclonal antibody was recently FDA-approved for active/severe GO.
6
Stimulatory thyrotropin receptor antibodies (TSH-R-Abs) are a specific biomarker for Graves disease and their measurement enables accurate, rapid differential diagnosis of hyperthyroidism.
7
Thyroid ultrasound is a sensitive imaging tool for diagnosing Graves disease.
8
Worldwide, thionamides for 12–18 months, specifically methimazole (MMI), are the favored initial treatment for newly diagnosed Graves disease.

Systemic autoimmune Graves disease (GD) and associated Graves orbitopathy (GO)

Clinical management strategies including diagnosis (TSH‑R‑Ab measurement, thyroid ultrasound), medical treatments (thionamides like methimazole, long-term low‑dose MMI, propylthiouracil in pregnancy), definitive therapies (radioactive iodine, total thyroidectomy), and treatment considerations for Graves orbitopathy and COVID‑19 interactions

Publication Details
Publication Date
2020-09-14
Journal
Publisher
ISSN
Cited by
231
Access Type
Author Information
Authors
George Jean Kahaly
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%